Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 543Squamous Cell Carcinoma of Head and Neck 280Head and Neck Neoplasms 257Lung Neoplasms 240Uterine Cervical Neoplasms 180Stomach Neoplasms 172Esophageal Neoplasms 161Nasopharyngeal Carcinoma 127Urinary Bladder Neoplasms 117Neoplasms 115Esophageal Squamous Cell Carcinoma 115Small Cell Lung Carcinoma 105Ovarian Neoplasms 92Breast Neoplasms 92Neoplasm Metastasis 89Cholangiocarcinoma 76Carcinoma, Squamous Cell 76Pancreatic Neoplasms 72Biliary Tract Neoplasms 71Oropharyngeal Neoplasms 57Mesothelioma, Malignant 57Carcinoma 55Adenocarcinoma Of Esophagus 52Recurrence 48Parkinson Disease 4, Autosomal Dominant Lewy Body 47Carcinoma, Ovarian Epithelial 46Nasopharyngeal Neoplasms 41Lymphoma 41Adenocarcinoma of Lung 41Gallbladder Neoplasms 39

Interventions

Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Neoplasms × Cisplatin × Clear all
NCT06132113 2026-05-27

DAREONâ„¢-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Boehringer Ingelheim

Phase 1 Recruiting
55 enrolled
Endocrine

Neuroendocrine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡